teclistamab-cqyv news

All news on teclistamab-cqyv (also known as TECVAYLI, teclistamab, and JNJ-6372): plants, production capacities, investments and involved companies.

29 May 2026

Johnson & Johnson: TECVAYLI improves PFS and OS in second-line multiple myeloma

Phase 3 MajesTEC‑9: teclistamab cut progression/death risk 71% (HR 0.29) and death 40% (HR 0.60) vs PVd/Kd in early RRMM; higher ≥CR (65.9% vs 16.8%); infections and CRS increased

Who will be producing teclistamab-cqyv in the future?

Find out with chemXplore Alpha

Learn more